Edwards Lifesciences (NYSE: EW) reported Q3 EPS of $1.07, $0.09 better than the analyst estimate of $0.98. Revenue for the quarter came in at $615 million versus the consensus estimate of $598.29 million.

Edwards Lifesciences sees FY2015 EPS of $4.43-$4.53, versus the consensus of $4.37. Edwards Lifesciences sees FY2015 revenue of $2.3-2.5 million, versus the consensus of $2.44 million.

Edwards Lifesciences sees Q4 2015 EPS of $1.11-$1.21, versus the consensus of $1.14. Edwards Lifesciences sees Q4 2015 revenue of $620-660 million, versus the consensus of $630.20 million.

For earnings history and earnings-related data on Edwards Lifesciences (EW) click here.